AstraZeneca
AstraZeneca to Share With Regulators Results From Truqap Trial in PTEN-Altered Prostate Cancer
Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.
NICE Not Backing AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Low Breast Cancer
Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.
The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
AstraZeneca's Tagrisso Gets Nod From EMA's CHMP in Unresectable EGFR-Mutated NSCLC
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
AstraZeneca Selects Diabetes Treg Cell Therapy Triggering $10M Payout for Quell Therapeutics
AstraZeneca will take the chosen type 1 diabetes product into preclinical and clinical studies and Quell will provide manufacturing support.